Sam Rasty brings more than 20 years of experience in biopharma leadership in companies ranging from early-stage startups to global industry incumbents. Most recently, he served as chief operating officer at Homology Medicines, a leader in gene therapy and gene editing. Prior to Homology he was vice president and head of new products at the Rare Disease Business Unit of Shire. Earlier in his career, Sam worked at Endo Pharmaceuticals and GlaxoSmithKline. He received a Ph.D. in biochemistry from Louisiana State University and an MBA from Villanova University.

Dr. Thon invented PBG’s platelet platform in his laboratory at Harvard Medical School, where he served as an assistant professor. He has published more than 30 peer-reviewed papers on the production and storage of platelets. He earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia, Vancouver. He retains a position as lecturer at Harvard Medical School.

Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.

Sam Rasty brings more than 20 years of experience in biopharma leadership in companies ranging from early-stage startups to global industry incumbents. Most recently, he served as chief operating officer at Homology Medicines, a leader in gene therapy and gene editing. Prior to Homology he was vice president and head of new products at the Rare Disease Business Unit of Shire. Earlier in his career, Sam worked at Endo Pharmaceuticals and GlaxoSmithKline. He received a Ph.D. in biochemistry from Louisiana State University and an MBA from Villanova University.

Dr. Thon invented PBG’s platelet platform in his laboratory at Harvard Medical School, where he served as an assistant professor. He has published more than 30 peer-reviewed papers on the production and storage of platelets. He earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia, Vancouver. He retains a position as lecturer at Harvard Medical School.

Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.

Joseph Italiano, Ph.D. is an associate professor at Harvard Medical School, where he leads his own lab focused on platelet production. He is also assistant professor in the Department of Surgery at Children’s Hospital Boston. Dr. Italiano earned his Ph.D. in cell biology from Florida State University. He is a co-founder of Platelet BioGenesis and chairman of the company’s scientific advisory board.

Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.